Investors Await AtheroGenics' Trial Results
Shares of AtheroGenics Inc. (AGIX) rose as investors await Phase III clinical trial results for the company's experimental heart medication AGI-1067. The stock price climbed $2.34 to close at $12.06.
posted by FC Market News at 10:34 AM
0 Comments:
Post a Comment
<< Home